Cargando…

Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis

BACKGROUND: Drug combination therapy is the frontline of malaria treatment. There is an ever-accelerating need for new, efficacious combination therapies active against drug resistant malaria. Proven drugs already in the treatment pipeline, such as the quinolines, are important components of current...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorka, Alexander P, Jacobs, Lauren M, Roepe, Paul D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874740/
https://www.ncbi.nlm.nih.gov/pubmed/24044530
http://dx.doi.org/10.1186/1475-2875-12-332
_version_ 1782297267639681024
author Gorka, Alexander P
Jacobs, Lauren M
Roepe, Paul D
author_facet Gorka, Alexander P
Jacobs, Lauren M
Roepe, Paul D
author_sort Gorka, Alexander P
collection PubMed
description BACKGROUND: Drug combination therapy is the frontline of malaria treatment. There is an ever-accelerating need for new, efficacious combination therapies active against drug resistant malaria. Proven drugs already in the treatment pipeline, such as the quinolines, are important components of current combination therapy and also present an attractive test bank for rapid development of new concepts. METHODS: The efficacy of several drug combinations versus chloroquine-sensitive and chloroquine-resistant strains was measured using both cytostatic and cytocidal potency assays. CONCLUSIONS: These screens identify quinoline and non-quinoline pairs that exhibit synergy, additivity, or antagonism using the fixed-ratio isobologram method and find tafenoquine – methylene blue combination to be the most synergistic. Also, interestingly, for selected pairs, additivity, synergy, or antagonism defined by quantifying IC(50) (cytostatic potency) does not necessarily predict similar behaviour when potency is defined by LD(50) (cytocidal potency). These data further support an evolving new model for quinoline anti-malarials, wherein haem and haemozoin are the principle target for cytostatic activity, but may not be the only target relevant for cytocidal activity.
format Online
Article
Text
id pubmed-3874740
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38747402013-12-31 Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis Gorka, Alexander P Jacobs, Lauren M Roepe, Paul D Malar J Research BACKGROUND: Drug combination therapy is the frontline of malaria treatment. There is an ever-accelerating need for new, efficacious combination therapies active against drug resistant malaria. Proven drugs already in the treatment pipeline, such as the quinolines, are important components of current combination therapy and also present an attractive test bank for rapid development of new concepts. METHODS: The efficacy of several drug combinations versus chloroquine-sensitive and chloroquine-resistant strains was measured using both cytostatic and cytocidal potency assays. CONCLUSIONS: These screens identify quinoline and non-quinoline pairs that exhibit synergy, additivity, or antagonism using the fixed-ratio isobologram method and find tafenoquine – methylene blue combination to be the most synergistic. Also, interestingly, for selected pairs, additivity, synergy, or antagonism defined by quantifying IC(50) (cytostatic potency) does not necessarily predict similar behaviour when potency is defined by LD(50) (cytocidal potency). These data further support an evolving new model for quinoline anti-malarials, wherein haem and haemozoin are the principle target for cytostatic activity, but may not be the only target relevant for cytocidal activity. BioMed Central 2013-09-18 /pmc/articles/PMC3874740/ /pubmed/24044530 http://dx.doi.org/10.1186/1475-2875-12-332 Text en Copyright © 2013 Gorka et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Gorka, Alexander P
Jacobs, Lauren M
Roepe, Paul D
Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis
title Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis
title_full Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis
title_fullStr Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis
title_full_unstemmed Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis
title_short Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis
title_sort cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874740/
https://www.ncbi.nlm.nih.gov/pubmed/24044530
http://dx.doi.org/10.1186/1475-2875-12-332
work_keys_str_mv AT gorkaalexanderp cytostaticversuscytocidalprofilingofquinolinedrugcombinationsviamodifiedfixedratioisobologramanalysis
AT jacobslaurenm cytostaticversuscytocidalprofilingofquinolinedrugcombinationsviamodifiedfixedratioisobologramanalysis
AT roepepauld cytostaticversuscytocidalprofilingofquinolinedrugcombinationsviamodifiedfixedratioisobologramanalysis